
Initiator Pharma Q1 2024 - Focus on sealing a deal

Redeye provides a research update following the Q1 report published by Initiator Pharma earlier today. The report did not include any significant surprises as the company continues to operate at a very low cash burn, showing promise for the financial runway ahead. Instead, we continue to argue that the full priority for 2024 will be to find a licensing partner for primarily pudafensine. We reiterate our fair value range with a base case valuation of SEK24 as we continue to have a strong outlook on the case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Initiator Pharma Q1 2024 - Focus on sealing a deal](#)